rubitecan has been researched along with Cancer of Prostate in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Braastad, CD; Chatterjee, D; Darnowski, J; Goldman, M; Goodglick, L; Pantazis, P; Wyche, JH | 1 |
Chatterjee, D; Pantazis, P; Wyche, JH | 1 |
Chatterjee, D; DeJesus, A; Early, J; Giovanella, B; Pantazis, P; Plaschke, S; Wyche, J | 1 |
Chatterjee, D; Kirchhoff, S; Krammer, PH; Krueger, A; Pantazis, P; Peter, ME; Schmitz, I; Wyche, JH; Yeung, K | 1 |
4 other study(ies) available for rubitecan and Cancer of Prostate
Article | Year |
---|---|
Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspases; Cloning, Molecular; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured | 2004 |
Induction of apoptosis in malignant and camptothecin-resistant human cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Cycle Proteins; DNA Topoisomerases, Type I; Drug Interactions; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Suramin; Tumor Cells, Cultured | 1996 |
Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Down-Regulation; Enzyme Activation; Enzyme Precursors; Fas Ligand Protein; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Glycoproteins; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured | 2001 |